Therapeutics

Top Story

New therapies target dry eye, conjunctivitis, redness, presbyopia

New therapies target dry eye, conjunctivitis, redness, presbyopia
June 23, 2017

WASHINGTON – Paul M. Karpecki, OD, FAAO, reported on new and up-and-coming ocular therapeutics at a continuing education session here at Optometry’s Meeting.

Allergan received FDA approval in April to market TrueTear intranasal tear neurostimulator.

Perspectives on Glaucoma

Higher rate of OSD seen in patients on glaucoma agents

June 19, 2017
In topical antiglaucoma therapy, the main factors impacting ocular surface disease were drops with preservatives, longer treatment duration and older age, according to…

Lifitegrast improved dry eye signs, symptoms in five trials

June 19, 2017
The combined clinical evidence from five trials supports the U.S. FDA approval of lifitegrast as a first-in-class medication for treating all signs and symptoms of dry…

Teva launches generic olopatadine solution

June 16, 2017
Teva Pharmaceutical Ind. has launched a generic version of Pataday, the company announced in a press release. Olopatadine HCl ophthalmic solution 0.2%, marketed by Alcon…
COPE

Diabetic Eye Disease - Volume 2, Number 1

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Video
Meeting News

VIDEO: Restasis multidose available soon

November 11, 2016
More »
Featured
Optometry's Meeting

Optometry's Meeting

Video
Meeting News

VIDEO: Débridement - First step in treating herpes simplex keratitis

March 6, 2017
More »
Meeting News

New therapies target dry eye, conjunctivitis, redness, presbyopia

June 23, 2017
WASHINGTON – Paul M. Karpecki, OD, FAAO, reported on new and up-and-coming ocular therapeutics at a continuing education session here at…

Perspectives on Glaucoma

Higher rate of OSD seen in patients on glaucoma agents

June 19, 2017
In topical antiglaucoma therapy, the main factors impacting ocular surface disease were drops with preservatives, longer treatment duration and older…

Lifitegrast improved dry eye signs, symptoms in five trials

June 19, 2017
The combined clinical evidence from five trials supports the U.S. FDA approval of lifitegrast as a first-in-class medication for treating all signs…

Teva launches generic olopatadine solution

June 16, 2017
Teva Pharmaceutical Ind. has launched a generic version of Pataday, the company announced in a press release. Olopatadine HCl ophthalmic solution…

PARx adds new features to prior authorization program

June 5, 2017
PARx Solutions, a company that helps eye care prescribers get preauthorization from insurance companies, has upgraded its platform by adding features…

In the Journals

Lifitegrast yields reproducible improvement in dry eye signs, symptoms

June 1, 2017
Reproducible, statistically significant data shows that lifitegrast improves the signs and symptoms of dry eye, especially in the mild to moderate…

Video

VIDEO: Long-term ocular pain requires oral treatment

May 24, 2017
NEPTUNE, N.J. – Anu Laul, OD, FAAO, shares a case of a patient experiencing long-term ocular nerve pain despite healing of the corneal surface…

Perspectives on Glaucoma

Systemic β-blockers have little effect on IOP reduction

May 23, 2017
Nonselective systemic -blocker intake showed a clinically relevant association and a borderline significant trend with IOP decrease, while the use of…

Meeting News

ARMOR study: Antibiotic resistance high among staphylococci

May 18, 2017
BALTIMORE – Researchers found high levels of antibiotic resistance among staphylococci, along with many isolates demonstrating multidrug…

FDA sets action date for OTC brimonidine drop

May 11, 2017
The FDA has accepted the New Drug Application for brimonidine tartrate ophthalmic solution and set a PDUFA action date for Dec. 27, according to a…

More Headlines »
Advertisement
Advertisement